Tucidinostat (Chidamide)

目录号:S8567 别名: HBI-8000, CS-055

仅限科研使用

Tucidinostat (Chidamide, HBI-8000, CS-055) 是HDAC1, 2, 3, 10的低摩尔浓度抑制剂,IC50分别为95、160、67、78 nM。

Tucidinostat (Chidamide) Chemical Structure

CAS: 1616493-44-7

规格 价格 库存 购买数量
10mM (1mL in DMSO) RMB 794.43 现货
RMB 795.33 现货
RMB 2023.28 现货
RMB 5299.86 现货
大包装 有超大折扣
大剂量询单有大折扣!

今日订购,明日送达 全国免运费 分装免费 分装成小规格产品(单支最小为1mg)
如1支10mg产品可分装为10支1mg产品

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Tucidinostat (Chidamide)发表文献12篇:

产品安全说明书

HDAC抑制剂选择性比较

相关HDAC产品

生物活性

产品描述 Tucidinostat (Chidamide, HBI-8000, CS-055) 是HDAC1, 2, 3, 10的低摩尔浓度抑制剂,IC50分别为95、160、67、78 nM。
靶点
HDAC3 [1]
(Cell-free)
HDAC10 [1]
(Cell-free)
HDAC1 [1]
(Cell-free)
HDAC2 [1]
(Cell-free)
67 nM 78 nM 95 nM 160 nM
体外研究

Chidamide抑制I型HDACs 1-3,以及IIb型HDAC10。在人类宫颈腺癌Hela细胞和人源PBMC细胞中,Chidamide显著地诱导组蛋白H3乙酰化。在微摩尔浓度范围内,Chidamide和MS-275可抑制大多数人源肿瘤细胞系的细胞生长,但并不是所有所检测的肿瘤细胞(共检测18种)。在人胚肾(CCC-HEK)和人胚肝(CCC-HEL)中,Chidamide对正常细胞的毒性作用比MS-275大大减少,说明Chidamide对正常细胞和癌细胞的细胞毒性作用的差异[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Sf9 NHLwfJZHfW6ldHnvckBie3OjeR?= NEK5dGQ2KG2rboO= M4XafmlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iZoXscEBt\W6pdHigTGRCSzFiZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKFOoOTDpcpNm[3RiY3XscJMhfXOrbnegZolwfGmweXzheIVlKGy7c3nu[UA6KGGlZYT5cIF1\WRiaHnzeI9v\SCKMzCoNUB1dyB{MTDy[ZNq\HWnczmgZZMhe3Wkc4TyZZRmKGmwY4XiZZRm\CCob4KgOUBucW6|IH\vcIxwf2WmIHL5JJN2[nO2cnH0[UBi\GSrdHnvckBu\WG|dYLl[EBi\nSncjC2NEBucSxiSVO1NEA:KDBwMUGyJO69VS5? NUfmcoNQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4N|U4QTdpPkK4PFM2Pzl5PD;hQi=>
EBC1 NYLST2VJSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NFLsV3E4OiCqcoO= NUTtU2JMSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDFRmMyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO|YYmsJGlEPTBiPTCyMlkh|ryPLh?= Mke4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6M{W3PVcoRjJ6OEO1O|k4RC:jPh?=
HCT116 M{\VSWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MVW3NkBpenN? MWTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR|UxKD1iNz64JO69VS5? MlvkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6M{W3PVcoRjJ6OEO1O|k4RC:jPh?=
HL60 MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVi0PEBpenN? M2C4fGdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhNPjBiY3XscJMhcW6ldXLheIVlKG[xcjC0PEBpenNiYomgUXRUKG2ndHjv[EwhT0l3MDC9JFAvPCEQvF2u MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzOlIyQTh6Lze+R4hGVUKOPD;hQi=>
Jurkat M1vsc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIfQRoI1QCCqcoO= MX3Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDKeZJs[XRiY3XscJMhcW6ldXLheIVlKG[xcjC0PEBpenNiYomgUXRUKG2ndHjv[EwhT0l3MDC9JFEvPSEQvF2u M3jlWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM3OjF7OEivK|5EcEWPQly8M4E,
hematopoietic malignant cells MXvDfZRwfG:6aXPpeJkh[XO|YYm= NETQVVJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBp\W2jdH;wc4lmfGmlIH3hcIlodmGwdDDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjygS2k2OCB;IEGuPFYh|ryPLh?= Mmm2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|YzOTl6OD:nQmNpTU2ETEyvZV4>
U2OS M13WUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NH3tPIw1QCCqcoO= NV[z[|gxT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hXTKRUzDj[YxteyCrbnP1ZoF1\WRiZn;yJFQ5KGi{czDifUBOXFNibXX0bI9lNCCJSUWwJF0hOiEQvF2u NFfaN489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{PjJzOUi4M{c,S2iHTVLMQE9iRg>?
HepG2 NUS4UIpXT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHjqWJY1QCCqcoO= NUi1Z4RLT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hUGWyR{KgZ4VtdHNiaX7jeYJifGWmIH\vdkA1QCCqcoOgZpkhVVSVIH3leIhw\CxiR1m1NEA:KDRizszNMi=> MnOzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|YzOTl6OD:nQmNpTU2ETEyvZV4>
LNCAP MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXTFTIJrPDhiaILz NFvrO2RIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBNVkODUDDj[YxteyCrbnP1ZoF1\WRiZn;yJFQ5KGi{czDifUBOXFNibXX0bI9lNCCJSUWwJF0hPCEQvF2u NVPwTYtCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzZ{MUm4PE8oRkOqRV3CUFww[T5?
Raji MmLVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGnqTXo1QCCqcoO= MXLHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDSZYpqKGOnbHzzJIlv[3WkYYTl[EBnd3JiNEigbJJ{KGK7IF3UV{Bu\XSqb3SsJGdKPTBiPTC0JO69VS5? M2LIblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM3OjF7OEivK|5EcEWPQly8M4E,
MCF7 MlzkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M4i5Z|Q5KGi{cx?= MkHLS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUWNHPyClZXzsd{BqdmO3YnH0[YQh\m:{IES4JIhzeyCkeTDNWHMhdWW2aH;kMEBIUTVyIE2gOUDPxE1w M1rzb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM3OjF7OEivK|5EcEWPQly8M4E,
28SC NV\HWZltT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MUO0PEBpenN? MV3Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjCyPHNEKGOnbHzzJIlv[3WkYYTl[EBnd3JiNEigbJJ{KGK7IF3UV{Bu\XSqb3SsJGdKPTBiPTC1Mlgh|ryPLh?= Mk[3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|YzOTl6OD:nQmNpTU2ETEyvZV4>
PANC1 M2HUS2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3LOWFQ5KGi{cx?= MnrRS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gVGFPSzFiY3XscJMhcW6ldXLheIVlKG[xcjC0PEBpenNiYomgUXRUKG2ndHjv[EwhT0l3MDC9JFYvOyEQvF2u MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzOlIyQTh6Lze+R4hGVUKOPD;hQi=>
human solid tumor cells NH\wT2REgXSxdH;4bYNqfHliYYPzZZk> MoXYR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gd49tcWRidIXtc5Ih[2WubIOgZZN{\XO|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44tKEeLNUCgQUA3NjZ3IN88UU4> NYfsVVhVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzZ{MUm4PE8oRkOqRV3CUFww[T5?
HeLa NHzKTGFHfW6ldHnvckBie3OjeR?= M1e1U|ExKG2rboO= MWfJcohq[mm2aX;uJI9nKEiGQVOg[Y57gW2jdHnjJIFkfGm4aYT5JIlvKGi3bXHuJGhmVGFiY3XscJMhcW6ldXLheIVlKG[xcjCxNEBucW6|IHnuJJBz\XOnbnPlJI9nKHO3YoP0doF1\SCkeTDjc4xwemmvZYTybYMh[WO2aY\peJkh[XO|YYmsJGlEPTBiPTC3MlIh|ryPLh?= MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzOlIyQTh6Lze+R4hGVUKOPD;hQi=>
MDA-MB-231 M4LBU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MY[0PEBpenN? M{nkN2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgbY5kfWKjdHXkJIZweiB2ODDodpMh[nliTWTTJI1mfGixZDygS2k2OCB;IEeuPUDPxE1w NVfCWYNvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzZ{MUm4PE8oRkOqRV3CUFww[T5?
SMMC7721 NGfoOnBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFK5cXU1QCCqcoO= NHH6S3dIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBUVU2FN{eyNUBk\WyuczDpcoN2[mG2ZXSg[o9zKDR6IHjyd{BjgSCPVGOgcYV1cG:mLDDHTVUxKD1iMU[g{txONg>? NYPRc4VmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzZ{MUm4PE8oRkOqRV3CUFww[T5?
DU145 MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVm0PEBpenN? MnjaS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gSHUyPDViY3XscJMhcW6ldXLheIVlKG[xcjC0PEBpenNiYomgUXRUKG2ndHjv[EwhT0l3MDC9JFI2KM7:TT6= M3vhV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM3OjF7OEivK|5EcEWPQly8M4E,
HeLa NG[yOWpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV60PEBpenN? NEfBTmNIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJ\UyjIHPlcIx{KGmwY4XiZZRm\CCob4KgOFghcHK|IHL5JG1VWyCvZYToc4QtKEeLNUCgQUA1OCEQvF2u MoP3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|YzOTl6OD:nQmNpTU2ETEyvZV4>
U2OS NF\DXWVHfW6ldHnvckBie3OjeR?= NEj2dHEyKHWP NHrz[HczPCCqcoO= M1XVR2FkfGm4YYTpc44hd2ZiUGDBVmchMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iaIXtZY4hXTKRUzDj[YxteyCjdDCxJJVOKGmwIIDy[ZNmdmOnIH;mJFExKHWPIILvd4lodGm2YYrvcoUhcW6ldXLheIVlKG[xcjCyOEBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6 MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzOlIyQTh6Lze+R4hGVUKOPD;hQi=>
U2OS MkXXSpVv[3Srb36gZZN{[Xl? M1\v[|EhfU1? MnLGNlQhcHK| MULBZ5RqfmG2aX;uJI9nKEWUYnX0ZUApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCqdX3hckBWOk:VIHPlcIx{KGG2IEGgeW0hcW5icILld4Vv[2Vib3[gNE4xOSC3TTDFNkBqdmO3YnH0[YQh\m:{IEK0JIhzeyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZk> NEnhe5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{PjJzOUi4M{c,S2iHTVLMQE9iRg>?
U2OS NHXHRZRHfW6ldHnvckBie3OjeR?= NFKwZpQyKHWP NW\KdY14OjRiaILz NVj2bIhTSWO2aY\heIlwdiCxZjDncJVt[2:lb4L0bYNwcWRicnXj[ZB1d3JiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gbJVu[W5iVULPV{Bk\WyuczDheEAyKHWPIHnuJJBz\XOnbnPlJI9nKDBwMTD1UUBl\XijbXX0bIF{d26nIHnuZ5Vj[XSnZDDmc5IhOjRiaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeR?= NWDW[FB5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzZ{MUm4PE8oRkOqRV3CUFww[T5?
U2OS NUPYbYV7TnWwY4Tpc44h[XO|YYm= M3nsVVEhfU1? Mm\UNlQhcHK| M4\KV2FkfGm4YYTpc44hd2ZiRWLhcJBp[SBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDoeY1idiCXMl;TJINmdGy|IHH0JFEhfU1iaX6gdJJme2WwY3Wgc4YhOC5yMTD1UUBGOiCrbnP1ZoF1\WRiZn;yJFI1KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[Xl? MmD6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|YzOTl6OD:nQmNpTU2ETEyvZV4>
U2OS MYrGeY5kfGmxbjDhd5NigQ>? M1fvbFEhfU1? NGHaOG8zPCCqcoO= M1K4TWFkfGm4YYTpc44hd2ZiZ3z1cINw[2:{dHnjc4llKHKnY3XweI9zKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIHj1cYFvKFV{T2OgZ4VtdHNiYYSgNUB2VSCrbnP1ZoF1\WRiZn;yJFI1KGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[Xl? MlPxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|YzOTl6OD:nQmNpTU2ETEyvZV4>
U2OS NVv2WlUzTnWwY4Tpc44h[XO|YYm= NEfxcpYyKHWP MWWyOEBpenN? MmP5RYN1cX[jdHnvckBw\iCSUFHSS{ApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCqdX3hckBWOk:VIHPlcIx{KGG2IEGgeW0hcW6ldXLheIVlKG[xcjCyOEBpenNiYomgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHzd4F6 MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzOlIyQTh6Lze+R4hGVUKOPD;hQi=>
U2OS NF:yelNHfW6ldHnvckBie3OjeR?= NEjJc|EyKHWP MXiyOEBpenN? M1XXd2FkfGm4YYTpc44hd2ZiRWLhcJBp[SBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDoeY1idiCXMl;TJINmdGy|IHH0JFEhfU1iaX7jeYJifGWmIH\vdkAzPCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7 MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzOlIyQTh6Lze+R4hGVUKOPD;hQi=>
U2OS M2\mPWZ2dmO2aX;uJIF{e2G7 MYqxJJVO NX3xO5JwOjRiaILz NUXBVW9OSWO2aY\heIlwdiCxZjDFVoJmfGFiKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gbJVu[W5iVULPV{Bk\WyuczDheEAyKHWPIHnuZ5Vj[XSnZDDmc5IhOjRiaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeR?= MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzOlIyQTh6Lze+R4hGVUKOPD;hQi=>
Assay
Methods Test Index PMID
Western blot PARP / Cleaved PARP / Caspase-3 / Cleaved caspase-3 p-EGFR / EGFR / p-STAT3 / STAT3 / p-AKT / AKT / p-AMPK / MAPK Ace-H3K18 / Ace-H3K9 / Ac-H4K8 Mcl-1 / Myc / Bcl-xl / p21 / p27 / CDK6 / CDK4 / Cyclin D2 HDAC1 / HDAC2 / HDAC3 / acetyl-H3 / acetyl-H4 30854137 29773595 31289512
Growth inhibition assay Cell viability 29100410
体内研究 在小鼠结肠癌HCT-8移植瘤模型中,Chidamide具有体内抗肿瘤活性。给药浓度范围为12.5-50 mg/kg的Chidamide可浓度依赖性地减少肿瘤大小和重量。Chidamide的给药浓度为50 mg/kg时,相较于对照药物组5-FU(20 mg/kg)和MS-275组(25 mg/kg)具有相似甚至更大的功效。在携瘤动物模型中,Chidamide耐受良好[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:

[1]

  • Cell lines: PBMC效应细胞
  • Concentrations: 0-400 nM
  • Incubation Time: 24-72 h
  • Method:

    将分离的PBMC效应细胞接种于6孔板(细胞密度为6 x 106 cells/孔),用不同浓度的chidamide(0-400 nM)处理细胞一定时间(24-72 h)。

动物实验:

[1]

  • Animal Models: Athymic nude mice (BALB/c-nu)
  • Dosages: 12.5-50 mg/kg
  • Administration: oral

溶解度(25°C)

体外

体内

从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
1% CMC Na

30mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 390.41
化学式

C22H19FN4O2

CAS号 1616493-44-7
储存条件 3年 -20°C 粉状
2年 -80°C 溶于溶剂

动物体内配方计算器(澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)

mg/kg g μL

第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)

% DMSO % % Tween 80 % ddH2O
%DMSO %

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于μL DMSO溶液(母液浓度mg/mL,:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);

体内配方配制方法:μL DMSO母液,加入μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入μL ddH2O,混匀澄清。

体内配方配制方法:μL DMSO母液,加入μL Corn oil,混匀澄清。

注意:1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

摩尔浓度计算器

质量 浓度 体积 分子量

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05141357 Not yet recruiting Drug: HBI-8000 in combination with pembrolizumab Non Small Cell Lung Cancer HUYABIO International LLC. December 2021 Phase 2
NCT04994210 Not yet recruiting Drug: Sintilimab|Drug: Chidamide Safety and Efficacy Sun Yat-sen University September 1 2021 Phase 2
NCT05140616 Recruiting Drug: Chidamide Safety and Efficacy The First Affiliated Hospital of Soochow University May 31 2021 Phase 1|Phase 2
NCT04651127 Recruiting Drug: Toripalimab + Chidamide Cervical Cancer|Cervix Cancer|Cervix Neoplasm Sun Yat-sen University November 9 2020 Phase 1|Phase 2
NCT03820596 Recruiting Drug: Sintilimab|Drug: Chidamide Safety and Efficacy Huiqiang Huang|Sun Yat-sen University March 29 2019 Phase 1|Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

* 必填项

请输入您的姓名
请输入您的邮箱地址 请输入一个有效的邮箱地址
请写点东西给我们